These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28434350)

  • 21. Amyloid polyneuropathy caused by wild-type transthyretin.
    Lam L; Margeta M; Layzer R
    Muscle Nerve; 2015 Jul; 52(1):146-9. PubMed ID: 25557530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A designer drug for amyloid polyneuropathy.
    Chalk C
    Neurology; 2012 Aug; 79(8):730-1. PubMed ID: 22843277
    [No Abstract]   [Full Text] [Related]  

  • 23. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis.
    Mathew V; Wang AK
    Drug Des Devel Ther; 2019; 13():1515-1525. PubMed ID: 31118583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S; Rossello A; Orlandini E
    ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A sporadic case of late-onset familial amyloid polyneuropathy type I (transthyretin Met 30-associated familial amyloid polyneuropathy) inborn habitant of Ehime prefecture].
    Harada T; Ishizaki F; Togo M; Yamashita H; Nitta K; Date Y; Nakazato M; Yamamura Y; Nakamura S
    No To Shinkei; 2002 Jul; 54(7):615-9. PubMed ID: 12187722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathogenesis and therapy for transthyretin related amyloidosis].
    Ando Y; Jono H
    Rinsho Byori; 2008 Feb; 56(2):114-20. PubMed ID: 18402051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
    Sekijima Y
    Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refine penetrance estimates in the main pathogenic variants of transthyretin hereditary (familial) amyloid polyneuropathy (TTR-FAP) using a new non-parametric approach (NPSE).
    Gorram F; Alarcon F; Perdry H; Hébrard B; Damy T; Fanen P; Funalot B; Nuel G; Planté-Bordeneuve V
    Amyloid; 2017 Mar; 24(sup1):115-116. PubMed ID: 28434346
    [No Abstract]   [Full Text] [Related]  

  • 29. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.
    Schmidt HH; Barroso F; González-Duarte A; Conceição I; Obici L; Keohane D; Amass L
    Muscle Nerve; 2016 Sep; 54(3):353-60. PubMed ID: 27273296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simple detection of abnormal serum transthyretin from patients with familial amyloidotic polyneuropathy by high-performance liquid chromatography/electrospray ionization mass spectrometry using material precipitated with specific antiserum.
    Kishikawa M; Nakanishi T; Miyazaki A; Shimizu A; Nakazato M; Kangawa K; Matsuo H
    J Mass Spectrom; 1996 Jan; 31(1):112-4. PubMed ID: 8799265
    [No Abstract]   [Full Text] [Related]  

  • 31. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina].
    Chaves M; Bettini M; Marciano S; Sáez S; Cristiano E; Rugiero M
    Medicina (B Aires); 2016; 76(2):105-8. PubMed ID: 27135849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
    Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
    J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G > T, p.Ala140Ser).
    Patel K; Tagoe C; Bieri P; Weidenheim K; Tauras JM
    Amyloid; 2018 Sep; 25(3):211-212. PubMed ID: 30039724
    [No Abstract]   [Full Text] [Related]  

  • 35. Transthyretin-type cerebral amyloid angiopathy: a serious complication in post-transplant patients with familial amyloid polyneuropathy.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):124. PubMed ID: 25112309
    [No Abstract]   [Full Text] [Related]  

  • 36. Coexistence of transthyretin familial amyloid polyneuropathy and hereditary neuropathy with liability to pressure palsy.
    Conceição I; Nzwalo H; de Carvalho M
    Clin Neurol Neurosurg; 2012 Dec; 114(10):1355-7. PubMed ID: 22520972
    [No Abstract]   [Full Text] [Related]  

  • 37. Transthyretin-related familial amyloidotic polyneuropathy.
    Ando Y; Nakamura M; Araki S
    Arch Neurol; 2005 Jul; 62(7):1057-62. PubMed ID: 16009758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
    Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
    Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical variant of familial amyloid polyneuropathy.
    Quan D; Cohen JA
    Muscle Nerve; 2002 Sep; 26(3):417-20. PubMed ID: 12210373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural stabilization of transthyretin by a new compound, 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione.
    Yokoyama T; Takaki S; Chosa K; Sato T; Suico MA; Teranishi Y; Shuto T; Mizuguchi M; Kai H
    J Pharmacol Sci; 2015 Dec; 129(4):240-3. PubMed ID: 26639444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.